<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03592316</url>
  </required_header>
  <id_info>
    <org_study_id>2018021</org_study_id>
    <nct_id>NCT03592316</nct_id>
  </id_info>
  <brief_title>Impact of a Lower Extremity Amputation Pathway Protocol in Dysvascular Patients</brief_title>
  <official_title>Impact of a Lower Extremity Amputation Pathway Protocol in Dysvascular Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LEAP protocol is a prospective cohort study of dysvascular patients designed to determine&#xD;
      whether implementation of a multi-disciplinary lower extremity amputation protocol in the&#xD;
      peri-operative period can shorten post-operative length of stay in patients undergoing&#xD;
      trans-tibial or trans-femoral amputations. A consecutive sample of patients diagnosed with&#xD;
      peripheral vascular disease and/or diabetes requiring major lower extremity amputation will&#xD;
      be enrolled in the study and compared to retrospective controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Actual">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Through hospital discharge, approximately 3 days after surgery</time_frame>
    <description>The total hospital length of stay for the lower extremity amputation admission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Up to 6 months after surgery</time_frame>
    <description>Mortality during the follow-up period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse limb event</measure>
    <time_frame>Up to 6 months after surgery</time_frame>
    <description>Hematoma, infection, ischemia, and/or need for revision of amputation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital morbidity</measure>
    <time_frame>Through hospital discharge, approximately 3 days after surgery</time_frame>
    <description>Catheter Associated Urinary Tract Infection, Pneumonia, Deep Vein Thrmbosis, and/or Pulmonary Embolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to functional independence</measure>
    <time_frame>Up to 6 months after surgery</time_frame>
    <description>Time to return to functional independence at home</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Lower Extremity Amputation</condition>
  <arm_group>
    <arm_group_label>Lower Extremity Amputation Pathway</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will follow the Lower Extremity Amputation Pathway, which will include pre-operative consultations and earlier progression with physical therapy post-operatively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lower Extremity Amputation Pathway</intervention_name>
    <description>Pre-operatively: Subjects will meet with social work/case management, physical therapy, anesthesiology, and the prosthetist for the following: discuss expectations and rehabilitation; pain control options and consideration for epidural or nerve block; prosthetic treatment and care timeline.&#xD;
Post-operatively: Physical therapy will begin on post-op day 1 with increasing complexity through post-op day 3. On post-op day 3 the wound will be examined by the surgeon and subjects will be cleared for discharge.&#xD;
Quality of life surveys will be given at several time points during post-operative care.</description>
    <arm_group_label>Lower Extremity Amputation Pathway</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients &gt;18 years of age diagnosed with peripheral vascular disease and/or diabetes&#xD;
             mellitus&#xD;
&#xD;
          -  Patients undergoing trans-tibial or trans-femoral amputations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing amputation for trauma, malignancy, or necrotizing fasciitis with&#xD;
             no dysvascular diagnosis&#xD;
&#xD;
          -  Patients who have previously undergone an amputation&#xD;
&#xD;
          -  Patients who were unable to function independently prior to admission&#xD;
&#xD;
          -  Patients admitted to the ICU prior to surgery&#xD;
&#xD;
          -  Attending surgeon does not approve of the patient being enrolled&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leigh Ann O'Banion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Community Regional Medical Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>February 10, 2021</last_update_submitted>
  <last_update_submitted_qc>February 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

